# Regeneron Pharmaceuticals Inc. (REGN)

Source: https://www.quantisnow.com/company/REGN
Generated: 2026-11-22T22:02:55.246Z

- Ticker: REGN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 1991
- SEC CIK: 0000872589
- Website: regeneron.com

## About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

## Latest REGN news and filings

- 2026-11-19 21:07 UTC [SEC Form S-8] [SEC Form S-8 filed by Regeneron Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-regeneron-pharmaceuticals-inc-6800633)
- 2026-11-19 12:23 UTC [FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS](https://www.quantisnow.com/insight/fda-approval-for-livsayis-issued-to-regeneron-pharmaceuticals-6799848)
- 2026-11-19 12:00 UTC [Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)](https://www.quantisnow.com/insight/regeneron-highlights-new-data-across-malignant-and-classical-hematology-programs-6799793)
- 2026-11-18 23:03 UTC [Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing](https://www.quantisnow.com/insight/livsayis-cemdisiran-approved-by-the-fda-as-first-and-only-6799436)
- 2026-11-18 21:13 UTC [SEC Form 4] [Director George L Sing sold $1,917,945 worth of shares (2,000 units at $958.97), decreasing direct ownership by 8% to 23,147 units (SEC Form 4)](https://www.quantisnow.com/insight/director-george-l-sing-sold-1917945-worth-of-shares-2000-6798794)
- 2026-11-18 21:10 UTC [SEC Form 4] [EVP Commercial Marion Mccourt sold $543,504 worth of shares (566 units at $960.25) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 10,305 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-commercial-marion-mccourt-sold-543504-worth-of-shares-566-6798762)
- 2026-11-18 21:07 UTC [SEC Form 4] [Co-Chief Scientific Officer Andrew J Murphy exercised 17,000 shares at a strike of $381.92, covered exercise/tax liability with 11,989 shares and sold $4,799,336 worth of shares (5,011 units at $957.76) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/co-chief-scientific-officer-andrew-j-murphy-exercised-17000-shares-at-6798741)
- 2026-11-17 12:00 UTC [Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications](https://www.quantisnow.com/insight/libtayo-cemiplimab-approved-in-the-european-union-eu-for-extended-6795585)
- 2026-11-12 22:00 UTC [POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms](https://www.quantisnow.com/insight/pots-phase-2-trial-shows-baloncibart-a-first-in-class-npr1-blocking-6788669)
- 2026-11-08 21:00 UTC [Earnings Date] [CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD](https://www.quantisnow.com/insight/cideb-sirna-normalizes-liver-fat-and-improves-liver-injury-markers-6779799)
- 2026-11-06 21:01 UTC [SEC Form 4] [SVP Controller Pitofsky Jason exercised 3,883 shares at a strike of $640.66 and sold $3,827,159 worth of shares (4,062 units at $942.19) (SEC Form 4)](https://www.quantisnow.com/insight/svp-controller-pitofsky-jason-exercised-3883-shares-at-a-strike-6778775)
- 2026-11-05 21:09 UTC [SEC Form 4] [Co-Chief Scientific Officer Murphy Andrew J gifted 1,054 shares, decreasing direct ownership by 2% to 46,779 units (SEC Form 4)](https://www.quantisnow.com/insight/co-chief-scientific-officer-murphy-andrew-j-gifted-1054-shares-decreasing-6776428)
- 2026-11-05 21:05 UTC [SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-13f-hr-filed-by-regeneron-pharmaceuticals-inc-6776248)
- 2026-11-05 21:05 UTC [SEC Form 4] [Director Zoghbi Huda Y exercised 7,439 shares at a strike of $380.95 and sold $7,219,274 worth of shares (7,439 units at $970.46) (SEC Form 4)](https://www.quantisnow.com/insight/director-zoghbi-huda-y-exercised-7439-shares-at-a-strike-6776223)
- 2026-11-04 21:11 UTC [SEC Form 4] [Director Sing George L exercised 15,269 shares at a strike of $378.77 and sold $20,376,358 worth of shares (21,129 units at $964.38), decreasing direct ownership by 19% to 25,147 units (SEC Form 4)](https://www.quantisnow.com/insight/director-sing-george-l-exercised-15269-shares-at-a-strike-6772644)
- 2026-11-04 21:09 UTC [SEC Form 4] [Director Poon Christine A exercised 7,830 shares at a strike of $376.69 and sold $7,587,958 worth of shares (7,830 units at $969.09) (SEC Form 4)](https://www.quantisnow.com/insight/director-poon-christine-a-exercised-7830-shares-at-a-strike-6772605)
- 2026-11-04 21:07 UTC [SEC Form 4] [EVP Finance CFO Fenimore Christopher R. exercised 6,000 shares at a strike of $381.92, covered exercise/tax liability with 4,243 shares and gifted 15 shares, increasing direct ownership by 9% to 21,726 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-finance-cfo-fenimore-christopher-r-exercised-6000-shares-at-6772525)
- 2026-11-04 21:04 UTC [SEC Form 4] [EVP General Counsel and Secret Larosa Joseph J exercised 12,283 shares at a strike of $381.92, covered exercise/tax liability with 8,686 shares and sold $4,311,890 worth of shares (4,466 units at $965.49), decreasing direct ownership by 2% to 38,906 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-general-counsel-and-secret-larosa-joseph-j-exercised-12283-6772318)
- 2026-11-03 21:22 UTC [SEC Form 4] [Director Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $360,000 worth of shares (400 units at $900.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-guarini-kathryn-exercised-400-shares-at-a-strike-of-6769975)
- 2026-11-03 21:05 UTC [SEC Form 4] [Director Brown Michael S exercised 1,929 shares at a strike of $725.89 and sold $1,687,875 worth of shares (1,929 units at $875.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-brown-michael-s-exercised-1929-shares-at-a-strike-6769567)
- 2026-11-03 21:02 UTC [SEC Form 4] [EVP Commercial Mccourt Marion sold $984,195 worth of shares (1,132 units at $869.43) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 10,871 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-commercial-mccourt-marion-sold-984195-worth-of-shares-1132-6769399)
- 2026-11-02 21:05 UTC [Conference Announcement] [Regeneron Announces Investor Conference Presentations](https://www.quantisnow.com/insight/regeneron-announces-investor-conference-presentations-6766981)
- 2026-10-30 10:55 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-regeneron-pharmaceuticals-inc-6764428)
- 2026-10-30 10:50 UTC [SEC Form 8-K] [Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/regeneron-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6764414)
- 2026-10-26 11:00 UTC [Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness](https://www.quantisnow.com/insight/regeneron-extends-agreement-with-barda-to-provide-additional-supply-of-6756884)
- 2026-10-25 09:15 UTC [Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)](https://www.quantisnow.com/insight/libtayo-cemiplimab-longer-term-data-show-increasing-and-clinically-meaningful-overall-6756739)
- 2026-10-16 11:00 UTC [Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types](https://www.quantisnow.com/insight/libtayo-cemiplimab-recommended-for-eu-approval-by-the-chmp-for-6748630)
- 2026-10-15 20:02 UTC [SEC Form 4] [Co-Chief Scientific Officer Murphy Andrew J sold $3,204,376 worth of shares (4,147 units at $772.70) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/co-chief-scientific-officer-murphy-andrew-j-sold-3204376-worth-of-6747991)
- 2026-10-12 16:06 UTC [Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension](https://www.quantisnow.com/insight/pasatru-garetosmab-grts-demonstrates-zero-new-heterotopic-ossification-ho-lesions-in-6743675)
- 2026-10-06 11:51 UTC [SEC Form 8-K] [SEC Form 8-K filed by Regeneron Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-regeneron-pharmaceuticals-inc-6738146)
- 2026-10-06 11:00 UTC [Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026](https://www.quantisnow.com/insight/regeneron-showcases-advances-in-care-across-several-cancers-and-cancer-associated-6738030)
- 2026-10-01 15:35 UTC [Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)](https://www.quantisnow.com/insight/ubamatamab-muc16xcd3-shows-a-high-rate-of-durable-responses-in-6731971)
- 2026-10-01 15:30 UTC [Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss](https://www.quantisnow.com/insight/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-6731964)
- 2026-10-01 12:39 UTC [Analyst Upgrade] [Regeneron Pharma upgraded by Argus with a new price target](https://www.quantisnow.com/insight/regeneron-pharma-upgraded-by-argus-with-a-new-price-target-6731644)
- 2026-10-01 05:00 UTC [Earnings Date] [Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies](https://www.quantisnow.com/insight/press-release-sanofi-and-regeneron-expand-global-alliance-with-multiple-6731128)
- 2026-10-01 05:00 UTC [Earnings Date] [Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies](https://www.quantisnow.com/insight/regeneron-and-sanofi-expand-global-alliance-with-multiple-next-generation-long-acting-6731126)
- 2026-09-30 20:14 UTC [SEC Form 8-K] [Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/regeneron-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-6730659)
- 2026-09-24 20:05 UTC [Earnings Date] [Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026](https://www.quantisnow.com/insight/regeneron-to-report-third-quarter-2026-financial-and-operating-results-6725342)
- 2026-09-03 20:50 UTC [SEC Form 4] [EVP Commercial Mccourt Marion sold $2,002,458 worth of shares (2,346 units at $853.56) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 12,003 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-commercial-mccourt-marion-sold-2002458-worth-of-shares-2346-6705523)
- 2026-09-03 20:47 UTC [SEC Form 4] [Director Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $340,000 worth of shares (400 units at $850.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-guarini-kathryn-exercised-400-shares-at-a-strike-of-6705499)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/REGN
- Earnings history: https://www.quantisnow.com/earnings/REGN
- Dividend history: https://www.quantisnow.com/dividends/REGN
- Insider transactions: https://www.quantisnow.com/insiders/REGN
- Options chain: https://www.quantisnow.com/options/REGN
- SEC 8-K filings only: https://www.quantisnow.com/company/REGN/8-k
- RSS and alerts for REGN: https://www.quantisnow.com/docs/rss-feeds.md
